Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907693 | 0.85 | MAPT (0.43) | MAPTPRKCATDP1RECQLELANE | |
| SCHEMBL18856309 | 0.83 | PRKCA (0.41) | MAPTPRKCAMMP1MMP2MMP3 | |
| SCHEMBL9744311 | 0.83 | MAPT (0.42) | MAPTPRKCATDP1RECQLELANE | |
| SCHEMBL21474533 | 0.83 | MAPT (0.39) | MAPTPRKCATDP1ALDH1A1RECQL | |
| SCHEMBL30547120 | 0.83 | TDP1 (0.47) | MAPTPRKCAMMP1MMP2MMP3 | |
| SCHEMBL5033123 | 0.83 | PRKCA (0.42) | PRKCAMMP1MMP2MMP3MMP9 | |
| SCHEMBL5859548 | 0.82 | MGAM (0.50) | MAPTPRKCATDP1ALDH1A1ELANE | |
| SCHEMBL30320231 | 0.82 | MAPT (0.47) | MAPTTDP1ALDH1A1ELANECYP3A4 | |
| SCHEMBL2854978 | 0.82 | MAPT (0.47) | MAPTTDP1ALDH1A1ELANECYP3A4 | |
| SCHEMBL14672451 | 0.82 | MAPT (0.47) | MAPTPRKCATDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260096574-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | VOYAGE FOODS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260007144-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | VOYAGE FOODS INC (US) | 2026-01-08 | — | — | US | claimed |
| EP-4606226-A2 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | Voyage Foods, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| EP-4578292-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | Voyage Foods, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| CN-119799505-A | Natural geotrichum candidum (Geotrichum candidum) and application thereof | 蘑米(广州)生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20250072446-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | Voyage Foods, Inc. | 2025-03-06 | — | — | US | claimed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | claimed |
| US-20250008978-A1 | COFFEE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | Voyage Foods, Inc. | 2025-01-09 | — | — | US | claimed |
| EP-4255208-B1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | VOYAGE FOODS INC (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4470389-A2 | COFFEE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | Voyage Foods, Inc. (US) | 2024-12-04 | — | — | EP | claimed |
| EP-1697386-B1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GEN ELECTRIC (US) | 2007-10-10 | — | — | EP | claimed |
| EP-1716159-A2 | CYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS | General Electronic Company (US) | 2006-11-02 | — | — | EP | claimed |
| EP-1697386-A1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | General Electric Company A Corporation of the State of New York (US) | 2006-09-06 | — | — | EP | claimed |
| US-20050245407-A1 | Fragrance composition | KAO CORPORATION (JP) | 2005-11-03 | — | — | US | claimed |
| CN-1674862-A | Perfume composition | KAO CORP (JP) | 2005-09-28 | — | — | CN | claimed |
| WO-2005066187-A1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GENERAL ELECTRIC COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005066186-A2 | CYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS | GENERAL ELECTRIC COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| EP-1552814-A1 | FRAGRANCE COMPOSITION | Kao Corporation (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20050136021-A1 | Active-releasing cyclic siloxanes | MOMENTIVE PERFORMANCE MATERIALS INC. | 2005-06-23 | — | — | US | claimed |
| US-20050136022-A1 | Cyclic siloxane compositions for the release of active ingredients | MOMENTIVE PERFORMANCE MATERIALS INC. | 2005-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007144-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | HAAO, PTGES2, PTGES | MAPT 3127/4885PRKCA 3826/4885MMP1 2512/4885 |
| US-20050136022-A1 | Cyclic siloxane compositions for the release of active ingredients | F9, RPL39, ECPAS | MAPT 815/4885PRKCA 3726/4885MMP1 541/4885 |
| US-20050136021-A1 | Active-releasing cyclic siloxanes | F9, RPL39, ALDH16A1 | MAPT 1453/4885PRKCA 3688/4885MMP1 198/4885 |
| US-20260096574-A1 | CHOCOLATE REPLICAS PRODUCED FROM INDIVIDUAL COMPONENTS | HAAO, HTR6, SCD | MAPT 1434/4885PRKCA 2946/4885MMP1 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.